These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27895670)

  • 1. Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a/PKC Signaling Pathway.
    Yang J; Zhang K; Wu J; Shi J; Xue J; Li J; Chen J; Zhu Y; Wei J; He J; Liu X
    Stem Cells Int; 2016; 2016():1690896. PubMed ID: 27895670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sox2 inhibits Wnt-β-catenin signaling and metastatic potency of cisplatin-resistant lung adenocarcinoma cells.
    He J; Shi J; Zhang K; Xue J; Li J; Yang J; Chen J; Wei J; Ren H; Liu X
    Mol Med Rep; 2017 Apr; 15(4):1693-1701. PubMed ID: 28259951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
    Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
    Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
    He J; Song X; Yu L; Li J; Qiao Z; Jiu R; Yu B; Liu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):625-9. PubMed ID: 25940289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line.
    Jin C; Song P; Pang J
    Oncol Lett; 2019 Oct; 18(4):3845-3856. PubMed ID: 31579410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-apoptotic brain and reproductive organ-expressed proteins enhance cisplatin resistance in lung cancer cells via the protein kinase B signaling pathway.
    Li Y; Qi K; Zu L; Wang M; Wang Y; Zhou Q
    Thorac Cancer; 2016 Mar; 7(2):190-8. PubMed ID: 27042221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin.
    Li W; Wang W; Ding M; Zheng X; Ma S; Wang X
    Cancer Cell Int; 2016; 16():30. PubMed ID: 27073334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway.
    Qi K; Li Y; Li X; Lei X; Wang B; Zhang L; Chu X
    Anticancer Drugs; 2016 Nov; 27(10):970-8. PubMed ID: 27537399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
    Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
    Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
    Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β-catenin signaling pathway.
    Wang Q; Geng F; Zhou H; Chen Y; Du J; Zhang X; Song D; Zhao H
    Oncol Lett; 2019 Oct; 18(4):4294-4307. PubMed ID: 31579066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.